Hawks Donald L III purchased $114K of SLQT

Hawks Donald L III purchased 250,000 shares of SelectQuote, Inc. (SLQT) at an average of $0.46 ($0.44–$0.46, $0.11M total) across 2 trades over 2026-11-06 to 2026-11-09.

Original reporting
SEC EDGAR · Hawks Donald L III
Published Nov 10, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SLQT
Bullish
medium confidence
Mentioned
$SLQT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SLQTBullishLow
01

Why it matters

The director's purchase modestly raises confidence in SelectQuote's outlook.

02

Market read

A small insider buy that may slightly influence short-term sentiment for SLQT.

03

What to watch

Potential upcoming product launches or earnings could amplify the effect of insider buying.

Relevance 5/10Novelty 5/10Timing: today after filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$SLQTBullishMedium confidence
Context

Director Hawks Donald L III bought 250,000 shares for $114,218, raising his holding to 763,214 shares.

Expected impact

likely slight upward pressure as market prices in insider buying

Evidence & confidence

The purchase is modest in size but represents a director increasing stake, which traders often view as a bullish signal.

Market effects

Minimal impact on insurance sector; only a single insider trade.

No broader regional effect.

Limited to investors tracking SelectQuote.

Counterpoint

The purchase is too small to move the stock; price may remain unchanged.

Key entities

  • SelectQuote, Inc.

    US-listed insurance technology firm (ticker SLQT).

  • Hawks Donald L III

    Director of SelectQuote who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SLQTMed

SelectQuote Inc (SLQT) (Q1 2027) Earnings Call Highlights: Beats EBITDA and Cash Flow

SelectQuote Inc (SLQT) reported Q1 2027 earnings, beating EBITDA and cash flow estimates. President Bob noted stable plan termination and high beneficiary engagement. CFO Ryan Clement highlighted progress toward a $60M operating cash flow target, with potential future cash dividends. CEO Tim Danker mentioned strong front-end production and improved recapture rates. The company is expanding its Olathe facility and investing in technology for other sites.

$SLQTMedAI 8/10

SelectQuote places fewer Medicare policies but earns more on each one

SelectQuote (SLQT) approved 18% fewer Medicare Advantage policies in Q1 2027, with revenue falling to $280M from $329M. However, commission values per policy rose 16% to $890. The company is shrinking its agent force to improve efficiency, and adjusted EBITDA losses narrowed. Healthcare Services revenue fell 16% but adjusted EBITDA rose 56%. SelectQuote maintained its full-year guidance and faces a False Claims Act lawsuit.

$SLQTMed

What SelectQuote (SLQT) Said on Its Q1 Earnings Call

SelectQuote (SLQT) reported Q1 earnings, with Senior revenue declining to $51M from $59M, but adjusted EBITDA loss narrowing. Healthcare Services revenue fell to $186M, while adjusted EBITDA rose 56% to $11M. Life Insurance revenue declined to $43M, but adjusted EBITDA increased 31% to $7M. The company plans a reverse stock split and invests in AI and technology. Management noted stability in commissions and potential carrier marketing efforts.

$SLQTMed

SelectQuote (SLQT) Q1 2027 Earnings Call Transcript

SelectQuote (SLQT) reported a Q1 2027 adjusted EBITDA loss of $17M, improved from last year. Revenue was $280M, down 15% YoY. Senior segment lost $12M (improved $9M YoY), while Healthcare Services EBITDA rose 56% YoY to $11M. The company reiterated its fiscal 2027 operating cash flow target of at least $60M, citing strong profitability and cash flow performance.

$SLQTMedAI 8/10

SelectQuote (SLQT) Q1 2027 Earnings Call Transcript

SelectQuote (SLQT) reported Q1 2027 revenue of $280M, down 15% YoY, with an adjusted EBITDA loss of $17M. Senior revenue fell 14% YoY, while Medicare Advantage policies decreased 18%. Healthcare Services revenue dropped 16%, but EBITDA grew 56%. The company maintained full-year guidance and plans a reverse stock split. Management prioritized profitability over volume, leveraging AI and operational efficiencies.